开始使用 Ustekinumab 或 Adalimumab 的晚期治疗无效或有经验的溃疡性结肠炎患者的实际治疗持续率。

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, Sabree Burbage, Aditi Shah, Jill Korsiak, Patrick Lefebvre, Caroline Kerner, Dominic Pilon
{"title":"开始使用 Ustekinumab 或 Adalimumab 的晚期治疗无效或有经验的溃疡性结肠炎患者的实际治疗持续率。","authors":"Maryia Zhdanava,&nbsp;Sumesh Kachroo,&nbsp;Porpong Boonmak,&nbsp;Sabree Burbage,&nbsp;Aditi Shah,&nbsp;Jill Korsiak,&nbsp;Patrick Lefebvre,&nbsp;Caroline Kerner,&nbsp;Dominic Pilon","doi":"10.1007/s12325-024-02942-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Persistence on advanced therapies in ulcerative colitis (UC) is a useful real-world treatment performance measure. This study compared real-world persistence during the maintenance phase among advanced therapy-naïve and -experienced patients with UC initiated on ustekinumab or adalimumab.</p><h3>Methods</h3><p>Claims data from the IQVIA PharMetrics<sup>®</sup> Plus de-identified database (01/01/2015–06/30/2022) were used to select adult patients with UC treated with ustekinumab or adalimumab based on the agent first initiated (index date) after 10/21/2019. Inverse probability of treatment weighting was used to balance cohorts on baseline characteristics. Persistence on the index agent (no gaps in days of supply of &gt; 120 days for ustekinumab or &gt; 60 days for adalimumab), persistence while corticosteroid-free, while on monotherapy, and persistence on the US labeled dose were described and compared during the 12-month period post-index using Kaplan–Meier analysis and Cox proportional hazards models. Outcomes were analyzed separately among advanced therapy-naïve and advanced therapy-experienced patients.</p><h3>Results</h3><p>At 12 months post-index, advanced therapy-naïve patients receiving ustekinumab (<i>n</i> = 371) had higher persistence on the index agent [83.8% vs. 57.6%, hazard ratio (95% confidence interval) = 3.09 (2.29–4.16); <i>p</i> &lt; 0.001), persistence while corticosteroid-free [2.00 (1.63–2.45); <i>p</i> &lt; 0.001], persistence while on monotherapy [2.67 (2.07–3.44); <i>p</i> &lt; 0.001], and persistence on the labeled dose [4.21 (2.76–6.44); <i>p</i> &lt; 0.001] versus those receiving adalimumab (<i>n</i> = 1726). At 12 months post-index, advanced therapy-experienced patients receiving ustekinumab (<i>n</i> = 693) had higher persistence on the index agent [78.1% vs. 59.2%, 2.44 (1.82–3.26); <i>p</i> &lt; 0.001], persistence while corticosteroid-free [1.24 (1.01–1.54); <i>p</i> = 0.0447], persistence while on monotherapy [2.53 (2.00–3.21); <i>p</i> &lt; 0.001], and persistence on the labeled dose [4.77 (3.09–7.35); <i>p</i> &lt; 0.001] versus those receiving adalimumab (<i>n</i> = 254).</p><h3>Conclusion</h3><p>This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-naïve and advanced therapy-experienced patients with UC initiated on ustekinumab compared to adalimumab.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 10","pages":"3868 - 3887"},"PeriodicalIF":3.4000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab\",\"authors\":\"Maryia Zhdanava,&nbsp;Sumesh Kachroo,&nbsp;Porpong Boonmak,&nbsp;Sabree Burbage,&nbsp;Aditi Shah,&nbsp;Jill Korsiak,&nbsp;Patrick Lefebvre,&nbsp;Caroline Kerner,&nbsp;Dominic Pilon\",\"doi\":\"10.1007/s12325-024-02942-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Persistence on advanced therapies in ulcerative colitis (UC) is a useful real-world treatment performance measure. This study compared real-world persistence during the maintenance phase among advanced therapy-naïve and -experienced patients with UC initiated on ustekinumab or adalimumab.</p><h3>Methods</h3><p>Claims data from the IQVIA PharMetrics<sup>®</sup> Plus de-identified database (01/01/2015–06/30/2022) were used to select adult patients with UC treated with ustekinumab or adalimumab based on the agent first initiated (index date) after 10/21/2019. Inverse probability of treatment weighting was used to balance cohorts on baseline characteristics. Persistence on the index agent (no gaps in days of supply of &gt; 120 days for ustekinumab or &gt; 60 days for adalimumab), persistence while corticosteroid-free, while on monotherapy, and persistence on the US labeled dose were described and compared during the 12-month period post-index using Kaplan–Meier analysis and Cox proportional hazards models. Outcomes were analyzed separately among advanced therapy-naïve and advanced therapy-experienced patients.</p><h3>Results</h3><p>At 12 months post-index, advanced therapy-naïve patients receiving ustekinumab (<i>n</i> = 371) had higher persistence on the index agent [83.8% vs. 57.6%, hazard ratio (95% confidence interval) = 3.09 (2.29–4.16); <i>p</i> &lt; 0.001), persistence while corticosteroid-free [2.00 (1.63–2.45); <i>p</i> &lt; 0.001], persistence while on monotherapy [2.67 (2.07–3.44); <i>p</i> &lt; 0.001], and persistence on the labeled dose [4.21 (2.76–6.44); <i>p</i> &lt; 0.001] versus those receiving adalimumab (<i>n</i> = 1726). At 12 months post-index, advanced therapy-experienced patients receiving ustekinumab (<i>n</i> = 693) had higher persistence on the index agent [78.1% vs. 59.2%, 2.44 (1.82–3.26); <i>p</i> &lt; 0.001], persistence while corticosteroid-free [1.24 (1.01–1.54); <i>p</i> = 0.0447], persistence while on monotherapy [2.53 (2.00–3.21); <i>p</i> &lt; 0.001], and persistence on the labeled dose [4.77 (3.09–7.35); <i>p</i> &lt; 0.001] versus those receiving adalimumab (<i>n</i> = 254).</p><h3>Conclusion</h3><p>This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-naïve and advanced therapy-experienced patients with UC initiated on ustekinumab compared to adalimumab.</p></div>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\"41 10\",\"pages\":\"3868 - 3887\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12325-024-02942-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02942-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

简介:溃疡性结肠炎(UC)晚期疗法的持续性是衡量真实世界治疗效果的一个有用指标。本研究比较了未接受过晚期疗法和有过晚期疗法治疗经验的 UC 患者在维持治疗阶段的实际坚持率:采用IQVIA PharMetrics® Plus去标识数据库(01/01/2015-06/30/2022)中的索赔数据,根据2019年10月21日之后首次启用的药剂(索引日期)选择接受乌司替尼或阿达木单抗治疗的成年UC患者。治疗的反概率加权用于平衡基线特征上的队列。使用 Kaplan-Meier 分析和 Cox 比例危险模型描述并比较了指数后 12 个月内指数药物的持续使用情况(乌斯特库单抗的供应天数间隔不超过 120 天,阿达木单抗的供应天数间隔不超过 60 天)、无皮质类固醇时的持续使用情况、单药治疗时的持续使用情况以及美国标注剂量的持续使用情况。对未接受过晚期治疗和接受过晚期治疗的患者的结果进行了分别分析:在指数后 12 个月,接受乌司替单抗治疗的晚期治疗无效患者(n = 371)对指数药物的持续耐受性更高[83.8% vs. 57.6%,危险比(95% 置信区间)= 3.09 (2.29-4.16);p 结论:这项基于索赔的分析表明,接受乌司替单抗治疗的晚期治疗无效患者对指数药物的持续耐受性更高:这项基于索赔的分析表明,与阿达木单抗相比,晚期治疗无效和晚期治疗经验丰富的UC患者的治疗持续率(包括无皮质类固醇时的持续率、单药治疗时的持续率和标注剂量的持续率)明显更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Introduction

Persistence on advanced therapies in ulcerative colitis (UC) is a useful real-world treatment performance measure. This study compared real-world persistence during the maintenance phase among advanced therapy-naïve and -experienced patients with UC initiated on ustekinumab or adalimumab.

Methods

Claims data from the IQVIA PharMetrics® Plus de-identified database (01/01/2015–06/30/2022) were used to select adult patients with UC treated with ustekinumab or adalimumab based on the agent first initiated (index date) after 10/21/2019. Inverse probability of treatment weighting was used to balance cohorts on baseline characteristics. Persistence on the index agent (no gaps in days of supply of > 120 days for ustekinumab or > 60 days for adalimumab), persistence while corticosteroid-free, while on monotherapy, and persistence on the US labeled dose were described and compared during the 12-month period post-index using Kaplan–Meier analysis and Cox proportional hazards models. Outcomes were analyzed separately among advanced therapy-naïve and advanced therapy-experienced patients.

Results

At 12 months post-index, advanced therapy-naïve patients receiving ustekinumab (n = 371) had higher persistence on the index agent [83.8% vs. 57.6%, hazard ratio (95% confidence interval) = 3.09 (2.29–4.16); p < 0.001), persistence while corticosteroid-free [2.00 (1.63–2.45); p < 0.001], persistence while on monotherapy [2.67 (2.07–3.44); p < 0.001], and persistence on the labeled dose [4.21 (2.76–6.44); p < 0.001] versus those receiving adalimumab (n = 1726). At 12 months post-index, advanced therapy-experienced patients receiving ustekinumab (n = 693) had higher persistence on the index agent [78.1% vs. 59.2%, 2.44 (1.82–3.26); p < 0.001], persistence while corticosteroid-free [1.24 (1.01–1.54); p = 0.0447], persistence while on monotherapy [2.53 (2.00–3.21); p < 0.001], and persistence on the labeled dose [4.77 (3.09–7.35); p < 0.001] versus those receiving adalimumab (n = 254).

Conclusion

This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-naïve and advanced therapy-experienced patients with UC initiated on ustekinumab compared to adalimumab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信